Developed as an inhibitor of specific proteins involved in cellular signaling pathways, this compound has potential as an anticancer agent, particularly for cancers with abnormalities in these proteins, such as lung, breast, and pancreatic cancer.

It inhibits the function of enzymes or proteins that promote cancer cell growth, slowing or stopping abnormal cell division. Additionally, it promotes cancer cell death (apoptosis) with minimal damage to normal cells, offering a safety advantage.

Recent research demonstrates its ability to inhibit tumor growth in animal models. Further studies are evaluating toxicity, bioavailability, and stability for future drug development.

Overall, it is a promising lead compound for new anticancer drugs, especially for cases resistant to conventional therapies.